Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells
J. Clin. Invest. Jeffrey J. Molldrem, et al. 111:639 doi:10.1172/JCI16398 [Go to this article.]

Figure 4
High-avidity PR1-specific CTLs are identified in the peripheral blood of (a) IFN sensitive CML patients in cytogenetic remission, but not in (b) IFN-resistant or in (c) untreated newly diagnosed CML patients. PBMCs were stained with CD8, dump (CD14 + CD19), and PR1-HLA-A2 tetramer. Patients 5–8 were treated for a minimum of 9 months with IFN. The percentage of Ph⁺ chromosomes in a simultaneous BM specimen is indicated above each FACS plot, and the percentage of CD8⁺ cells with high-avidity PR1-specific CTLs is indicated within each FACS plot.